||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


MorphoSys Announces Clinical Milestone in Cancer Program with Bayer Schering Pharma

Eighth HuCAL Antibody to Enter Clinical Trials

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced
today that Bayer Schering Pharma AG, Germany has filed all necessary
documentation to initiate a Phase 1 clinical trial with a
HuCAL-derived antibody-drug conjugate (ADC) in the therapeutic area
of oncology. This achievement marks a significant milestone within
the Bayer Schering Pharma alliance and triggers a payment to
MorphoSys.

"Today's news underlines how important our core technology is to the
pharmaceutical industry's drug pipeline," commented Dr. Simon
Moroney, Chief Executive Officer of MorphoSys AG. "We now have
clinical trials of HuCAL-based antibodies ongoing with four different
pharmaceutical companies. The output of our partners' application of
MorphoSys's proprietary HuCAL technology is becoming an increasingly
visible and important value driver for our Company."

The current program is directed against the target molecule MN, also
known as Carbonic Anhydrase or CA IX for short, a tumor associated
antigen expressed in many tumor types under hypoxic conditions. The
antibody is the first fully human HuCAL-based ADC to enter clinical
trials. ADCs comprise antibodies linked to cytotoxic drugs, and
combine the targeting properties of the antibody with the
cell-destroying effect of the conjugated drug. In the present
program, the HuCAL-derived antibody-drug conjugate incorporates
technology licensed to Bayer Schering Pharma from Seattle Genetics.

MorphoSys projected that in 2009 between two and four partnered
programs could enter clinical trials. Today's news represents the
third HuCAL-derived antibody to achieve this stage during the course
of the year. By the end of this year, at least three antibodies from
proprietary and partnered programs are expected to be in Phase 2
clinical trials. This program becomes the eighth HuCAL-derived
compound in all to enter clinical trials.


For further information please contact: Dr. Claudia Gutjahr-Löser,
Head of Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Senior
Manager Corporate Communications & Investor Relations, Tel: +49 (0)
89 / 899 27-454, brkulj@morphosys.com


About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel
antibodies for therapeutic, diagnostic and research applications. The
Company's HuCAL technology is one of the most powerful methods
available for generating fully human antibodies. By successfully
applying this and other proprietary technologies, MorphoSys has
become a leader in the field of therapeutic antibodies, one of the
fastest-growing drug classes in human health-care. Through its
alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The
Company is expanding its drug pipeline by adding new partnered
programs, and by building a portfolio of fully-owned therapeutic
antibodies. For its proprietary portfolio, the Company is focused on
the areas of oncology and inflammation, within which it plans to have
eight active programs by the end of 2009. Its most advanced program
is MOR103, a first-in-class, fully human antibody against GM-CSF.
MorphoSys expects to commence a Phase Ib/IIa trial of this antibody
in rheumatoid arthritis patients in the second half of 2009. Via its
business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock
Exchange under the symbol "MOR". For further information, visit
http://www.morphosys.com/

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered
trademarks of MorphoSys AG



This communication contains certain forward-looking statements
concerning the MorphoSys group of companies. The forward-looking
statements contained herein represent the judgment of MorphoSys as of
the date of this release and involve risks and uncertainties. Should
actual conditions differ from the Company's assumptions, actual
results and actions may differ from those anticipated. MorphoSys does
not intend to update any of these forward-looking statements as far
as the wording of the relevant press release is concerned.


This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.



 
 ||| Themen-Infos 
· Mehr zu dem Thema Contracts & Corporate events & IPOs &

Der meistgelesene Artikel zu dem Thema Contracts & Corporate events & IPOs &:
Change on the Board of Directors of Feintool Holding AG

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.071 Sekunden